Clinical Trials of a Stromelysin Inhibitor: Osteoarthritis, Matrix Metalloproteinase Inhibition, Cartilage Loss, Surrogate Markers, and Clinical Implications-Reference-Cited by-同舟云学术

Clinical Trials of a Stromelysin Inhibitor: Osteoarthritis, Matrix Metalloproteinase Inhibition, Cartilage Loss, Surrogate Markers, and Clinical Implications

Published:1999-06 Issue:1 INHIBITION OF Volume:878 Page:201-207
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Annals NY Acad Sci

Author:

LEFF RICHARD L.

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1749-6632.1999.tb07685.x/fullpdf

Reference12 articles.

1. 1Dequeker, J. & L. van de Putte. 1994. Disorders of bone, cartilage, and connective tissue.InRheumatology. J.H. Klippel & P.A. Dieppe, Eds. Mosby-Year Book Europe Ltd. London.

2. Matrix Metalloproteinases: A Review

3. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Current Role of Disease-modifying Osteoarthritis Drugs;ARCH BONE JT SURG-AB;2023

2. Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents;Journal of Controlled Release;2020-12

3. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks;Bone;2020-09

4. INFLAMMATION: A POTENTIAL SCENARIO ON NOVEL TARGETS AND TARGETED DRUG THERAPY;INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH;2019-12-01

5. Anti-arthritic agents: Progress and potential;Bioorganic & Medicinal Chemistry;2015-07